<DOC>
	<DOCNO>NCT00801216</DOCNO>
	<brief_summary>This prospective trial ass activity feasibility new high-dose methotrexate-based high-dose sequential chemotherapy combination patient B-cell lymphoma CNS involvement diagnosis relapse . Selected drug , well-documented anti-lymphoma activity , administer high dos increase blood-brain barrier penetration CNS bioavailability well reduce potential cross-resistance .</brief_summary>
	<brief_title>High-Dose Sequential Chemoimmunotherapy B-Cell Lymphomas With Central Nervous System Involvement</brief_title>
	<detailed_description>Patients aggressive B-cell lymphoma involvement central nervous system diagnosis relapse treat combination high-dose methotrexate high-dose cytarabine , rituximab , intrathecal depocyte follow rituximab-high-dose sequential chemotherapy support autologous tsem cell transplantation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Histologically confirm diagnosis diffuse largecell , follicular mantle cell lymphoma 2 . CNS involvement ( brain , meninges , cranial nerve , eye , and/or spinal cord ) diagnosis relapse conventional chemotherapy 3 . Diagnosis CNS involvement either brain biopsy CSF cytology examination . Neuroimaging alone acceptable stereotactic biopsy formally contraindicate . 4 . Age 1965 year 5 . ECOG performance status 03 6 . Adequate bone marrow ( PLT &gt; 100000 mm3 , Hb &gt; 9 g/dl , ANC &gt; 2.000 mm3 ) , renal ( creatinine clearance &gt; 60 mL/min ) , cardiac ( VEF &gt; 50 % ) , hepatic function ( total serum bilirubin &lt; 3 mg/dL , AST/ALT gammaGT &lt; 2.5 per upper normal limit value ) , within 1 week prior study start ( unless abnormality due lymphoma involvement ) 7 . Absence symptomatic coronary artery disease , cardiac arrhythmia well control medication myocardial infarction within last 6 month ( New York Heart Association Class III IV heart disease ) 8 . Absence HIV infection 9 . No previous concurrent malignancy exception surgically cure carcinoma insitu cervix carcinoma skin cancer without evidence disease least 5 year 10 . Absence familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 11 . Female patient must nonpregnant nonlactating . Sexually active patient childbearing potential must implement adequate contraceptive measure study participation 12 . No treatment experimental drug within 6 week previous enrolment 13 . Give write informed consent prior study specific procedure , understand patient right withdraw study time , without prejudice</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>B-cell lymphoma</keyword>
	<keyword>lymphomatous meningitis</keyword>
	<keyword>liposomal cytarabine</keyword>
	<keyword>autologous transplant</keyword>
	<keyword>CNS involvement</keyword>
	<keyword>Secondary CNS lymphoma</keyword>
</DOC>